The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...

This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...

Parekh is chief medical adviser at the Bipartisan Policy Center. Dietz is professor of exercise and nutritional sciences at the Milken Institute School of Public Health, George Washington ...